STATED AND DERIVED PREFERENCES OF TREATMENT ATTRIBUTES IN MODERATE-SEVERE PSORIASIS PATIENTS
نویسندگان
چکیده
منابع مشابه
Treatment Approaches to Moderate to Severe Psoriasis
Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this revie...
متن کاملDermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.
BACKGROUND Despite increasing therapies for moderate to severe psoriasis, dermatologists' treatment preferences are unknown. OBJECTIVE We sought to assess dermatologists' preferences for first-line treatments and their selection determinants. METHODS We surveyed 1000 US dermatologists (500 National Psoriasis Foundation and 500 American Academy of Dermatology members who treat psoriasis) abo...
متن کاملSerum vascular endothelial growth factor in Iranian patients with moderate-severe psoriasis before and after treatment: a PASI-75 response as a practical treatment goal
Background: Psoriasis is a chronic disease with multiple biochemical and vascular abnormalities. Several studies have evaluated circulating levels of vascular endothelial growth factor (VEGF) in psoriasis, but none of them evaluated it after reaching a PASI-75 response, as a practical treatment goal. The aim of this study was to evaluate serum levels of VEGF in moderate to severe psoriatic pati...
متن کاملApremilast in the treatment of moderate-to-severe plaque psoriasis:
2015 Psoriasis is a chronic, systemic inflammatory disease that often has a negative impact on daily functioning and quality of life. Although many treatment options are available, patients are often dissatisfied with their current disease management. Apremilast, an oral PDE4 inhibitor, was recently approved in multiple countries for the treatment of patients with active psoriatic arthritis and...
متن کاملUstekinumab for the treatment of moderate to severe psoriasis.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of ustekinumab for the treatment of moderate to severe psoriasis based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's main evid...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2016
ISSN: 1098-3015
DOI: 10.1016/j.jval.2016.03.1007